Is This Really the Next Obesity Drug?

By Brenton Flynn – Dec 14, 2012 at 7:00PM

NYSE: NVO

Novo Nordisk

Market Cap

$427B

Today's Change

(-1.93%) -$2.48

Current Price

$126.16

Price as of April 24, 2024, 4:00 p.m. ET

Already a blockbuster, this drug may now may be joining the obesity space.

Each week, we like to take a moment to boil down the biggest news from the most influential companies in the pharmaceuticals industry, and tell our viewers what that news means for you. We call that segment our Big Pharma Roundup.

In this week's installment, Brenton discusses a trial under way at Novo Nordisk (NVO -1.93%) with its drug Victoza. The drug is currently a blockbuster in the diabetes type 2 space, but NVO is testing higher dosages for use in obesity. In this video, he discusses whether this is important for other players in the obesity drug space.

Brenton Flynn has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.